Skylar Kenney, Assistant Editor

The study examined safety, immune response (immunogenicity), and adverse effects of 7 vaccines when used as a third booster jab.

The investigators said this increase in risk is particularly pronounced in those with more advanced disease.

According to the investigators, in vitro functional studies demonstrate potent antitumor activity of ATA2271 following repeat antigen stimulation.

The combination of tislelizumab and chemotherapy demonstrated a statistically significant improvement in progression-free survival.

The combination therapy of ibrutinib and venetoclax was superior to chlorambucil and obinutuzumab in terms of undetectable minimal residual disease responses in elderly or unfit patients with previously untreated chronic lymphocytic leukemia.

Although it was previously known that HZ incidence and HZ-related complications occur more frequently and with higher severity in solid organ transplant recipients, numbers varied extensively between studies.

According to the trial results, these responses appear durable, with a target dose-dependent increase in overall response rate without any increase in the rate of cytokine release syndrome.

Apotex, Sandoz, and Taro allegedly cause an increase in drug costs for federal health care programs and beneficiaries.

Daratumumab continued to demonstrate deep and durable responses, including improvements to stringent complete response (sCR) rates and minimal residual disease (MRD)-negativity.

The investigators found that modeling was a cost-effective method for determining the functionality of the proposed blueprint by transforming it into a physical space.

Although barcode scanning during product verification has greatly improved the safety of medication dispensing operations, many products aren’t easily incorporated into traditional dose preparation processes, including medications manually dispensed in oral syringes.

The investigators found that the ability to track the status of a medication in real-time may assist with communication gaps between departments and facilitate patient safety improvements.

The investigators said that there were no new safety signals identified, and no reported instances of tumor lysis syndrome.

The panelists reviewed current treatments for Clostridioides difficile infection and how they can be applied to special patient populations, as well as what treatments can be expected in the future.

Genomic analyses show promise for patients with metastatic breast cancer, reinforcing genomics as a part of the pathway of care.

Moderna COVID-19 vaccine found to offer an increased level of protection, including a 21% reduced risk of documented infection and 41% lower risk of hospitalization.

Pyrotinib combined with capecitabine found to improve overall survival in patients with previously treated HER2-positive metastatic breast cancer.

In the case reviewed, the pharmacy department created an interdisciplinary Biosimilar Task Force responsible for making decisions relating to the adoption of biosimilar therapies.

In the study, the investigators observed that by elevating technicians to advanced analytics roles, pharmacies could develop user-friendly data collection tools and data analytics.

The case study details the methodology employed by a large academic medical center to convert its medication history technician program’s workflow from on-site with in-person patient interviews to completely remote services.

The investigators compared blood test results from a total of 186 paramedics, some of whom received their second dose less than 4 weeks after receiving the first, whereas others received second doses after 6 to 7 weeks.

The workload in pharmacies may not be proportionate to census or patient load due to variations in case mix index.

Pharmacy leaders can be equipped to make effective decisions to support a successful work experience, regardless of work setting.

Involving students in advanced pharmacy practice experience rotations resulted in a greater overall impact.

Regular vaccine workflow re-education helps promote standard workflows and prevent vaccine errors.

Studies support the use of a COVID-19 vaccine booster dose to increase protection among immunocompromised individuals.

Multiple GBS vaccine candidates are in development, but none are available despite development efforts spanning multiple decades.

Ibrutinib in combination with venetoclax shows promise in patients with previously untreated chronic lymphocytic leukemia.

The researchers said these results reinforce the importance of a third booster dose of the vaccine.

Stem cell therapy was associated with a reduction of the number of heart attacks, strokes, and death among people with chronic, high-risk, NYHA class 2 or 3 heart failure with reduced ejection fraction (HFrEF), according to a study presented at the American Heart Association’s Scientific Sessions 2021.